How Theranos’ faulty blood tests got to market – and what that shows about gaps in FDA regulation || Ana Santos Rutschman :: The Conversation

One of the most high-profile trials of the year is underway to decide whether Theranos founder Elizabeth Holmes defrauded patients and investors. Read more

Author, Ana Santos Rutschman Assistant Professor of Law, Saint Louis University